Brightsurf Science News and Current Science News Events
 
Email a Friend Send to a friend
Printer Friendly Print Study finds cisplatin less effective than standard treatment for patients with anal cancer

Study finds cisplatin less effective than standard treatment for patients with anal cancer

April 23, 2008

Chemotherapy drug fails to improve disease-free survival; results in more colostomies

HOUSTON - When administered before chemoradiation, the common anti-cancer drug cisplatin neither improved disease-free survival nor reduced the number of colostomies needed when compared to the standard treatment for patients with anal canal cancer, according to a study published in the April 23 issue of the Journal of the American Medical Association.




In the largest cooperative phase III randomized controlled trial of its kind, a multicenter research team led by Jaffer Ajani, M.D., professor in the Department of Gastrointestinal Medical Oncology at The University of Texas M. D. Anderson Cancer Center, compared the standard treatment regimen of fluorouracil plus mitomycin and radiotherapy to fluorouracil plus cisplatin and radiotherapy in 644 patients with anal canal cancer. The five-year disease-free survival rate was 60 percent in the mitomycin-based group and 54 percent in the cisplatin-based group. The five-year overall survival rate was 75 percent in patients receiving mitomycin versus 70 percent receiving cisplatin, with more cancer-related deaths in the cisplatin-based group (54 patients) compared to mitomycin-based group (28 patients).

Patients who received cisplatin-based treatment resulted in significantly higher rates of colostomy (19 percent versus 10 percent). It is widely held among practicing oncologists that the colostomy procedure, which creates an alternative exit from the colon to divert waste, should only be used as a last resort in the treatment of anal canal cancer due to its considerable affect on the patient's quality of life.

"Based on preliminary data from smaller trials that suggested considerable sensitivity to the fluorouracil plus cisplatin combination, cisplatin has gained popularity among oncologists as a drug to treat anal canal cancer," said Ajani. "However, it is clear from this data that cisplatin is not the drug to use and its use should be discontinued in standard therapy."

The study expanded on findings from two pilot studies that encouraged oncologists to believe that cisplatin could potentially be used to reduce the cancer in the primary tumor and lymph nodes prior to administration of concurrent chemoradiation. The research group hypothesized that using cisplatin to downsize the tumors first could be an effective strategy for treating the disease because previous studies have established that chemoradiation is more effective for smaller anal canal carcinomas than larger ones.

"There have been incremental advancements in the treatment for anal canal cancer in the last decade and there was hope that the unique cisplatin-based strategy would offer an improved, less-toxic therapy to patients suffering from the disease," Ajani said. "While our research did not uncover a new standard of treatment, comparative studies such as this one are imperative to determining best practices and informing community oncologists."

According to the American Cancer Society, an estimated 5,070 new cases of anal canal cancer will be diagnosed in 2008. The five-year disease-free survival of approximately 65 percent has not improved since the early 1990s. Primary anal canal tumor size has a direct bearing on cure rates, and the five-year survival rates decrease significantly for tumors larger than 5 cm diameter. Approximately 25 percent of newly diagnosed anal carcinomas are larger than 5 cm in diameter.

From this study, it is anticipated that researchers will look to explore other options such as newer targeted therapies and intensity-modulated radiation plus concurrent chemotherapy to improve disease-free and colostomy-free survival relative to the continued standard of concurrent chemoradiation with fluorouracil and mitomycin.

University of Texas M. D. Anderson Cancer Center



Related Cisplatin News Articles Cisplatin News and Current Cisplatin Events RSS Cisplatin News and Current Cisplatin Events RSS
Variation of normal protein could be key to resistance to common cancer drug
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.

New clinical trial for patients with asbestos-associated lung cancer
The Mesothelioma Center within the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital and Columbia University Medical Center is now recruiting patients for a clinical research study of a new targeted radiation and chemotherapy protocol for pleural mesothelioma, a cancer of the lung's lining that is almost always caused by previous exposure to asbestos.

MIT researchers see alternative to common colorectal cancer drug
A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found.

Synergistic growth inhibitory effect of herbal extracts against HCC and lung cancer cells
Several herbs with diversified pharmacological properties are known to be rich sources of chemical constituents that may have potential for the treatment of several human cancers. Data from the Department of Preclinical Science, Faculty of Medicine, Thammasat University, demonstrates that the growth inhibitory activity of doxorubicin or cisplatin, as single agents, may be modified in combination with emblic myrobalan or belleric myrobalan extracts and may be synergistically enhanced in some cases.

Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.

Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
A team of researchers led by Fred Hutchinson Cancer Research Center has identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with commonly used platinum-based chemotherapy drugs such as cisplatin and carboplatin. They describe their research online Feb. 10 in the journal Nature.

Light powered platinum more targeted & 80 times more powerful than similar cancer treatments
Researchers from the Universities of Warwick, Edinburgh, Dundee and the Czech Republic's Institute of Biophysics have discovered a new light-activated platinum-based compound that is up to 80 times more powerful than other platinum-based anti-cancer drugs and which can use "light activation" to kill cancer cells in much more targeted way than similar treatments.

New treatment option studied for bladder cancer
A chemotherapy regimen for patients with advanced bladder cancer who aren't eligible for standard treatment is under study at the Medical College of Georgia.

Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
Mayo Clinic today reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin.

Genomic profiling of lung tumors helps doctors choose most effective treatment
Determining the genetic profile of a particular lung tumor can help clinicians make the crucial decision about which chemotherapy treatment to try first.
More Cisplatin News Articles


Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy

Infrared and Raman Spectra of Inorganic and Coordination Compounds, Applications in Coordination, Organometallic, and Bioinorganic Chemistry
by Kazuo Nakamoto

The 6th edition of this classic comprises the most comprehensive guide to infrared and Raman spectra of inorganic, organometallic, bioinorganic, and coordination compounds. From fundamental theories of vibrational spectroscopy to applications in a variety of compound types, it is extensively updated. Part B details applications of Raman and IR spectroscopy to larger and complex systems. It covers...



Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants [An article from: DNA Repair]
by A. Nowosielska, M.G. Marinus

This digital document is a journal article from DNA Repair, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: Escherichia coli dam cells are more susceptible to the cytotoxic action of cisplatin than wildtype. Dam mutS or dam mutL bacteria, however, are...

Weekly regimen not optimal for cisplatin: the finding is important, because about 5 years ago the weekly regimen became the standard of care.(Gynecology): An article from: OB GYN News
by Doug Brunk

This digital document is an article from OB GYN News, published by Thomson Gale on May 15, 2006. The length of the article is 591 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Weekly regimen not...

Cisplatin: Current Status and New Developments.

Effect of Cassia auriculata Linn. Root extract on cisplatin and gentamicin-induced renal injury.: An article from: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology
by S. Annie, P.L. Rajagopal, S. Malini

This digital document is an article from Phytomedicine: International Journal of Phytotherapy & Phytopharmacology, published by Thomson Gale on August 1, 2005. The length of the article is 3558 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view...



Immortalized mouse cell lines that lack a functional Rev3 gene are hypersensitive to UV irradiation and cisplatin treatment [An article from: DNA Repair]
by L. Zander, M. Bemark

This digital document is a journal article from DNA Repair, published by Elsevier in 2004. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: The catalytic subunit of polymerase @z is encoded from the Rev3 gene. The enzyme is conserved through eukaryotic evolution and its main...

Cisplatin: An entry from Thomson Gale's Gale Encyclopedia of Cancer, 2nd ed.
by Nancy, RPh., BCOP Beaulieu, Rebecca, PhD Frey

Students, researchers, and patients can find reliable, up-to-date and clearly written information in “The Gale Encyclopedia of Cancer,” a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic...

The Mechanism of Cisplatin Resistance and Its Circumvention

Platinol (cisplatin for injection) and Vepesid (etoposide): An effective combination chemotherapy regimen in solid tumors
by Nicholas Vogelzang

© 2008 BrightSurf.com